CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
60
About the Report
About the Report
Summary
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.
CTI BioPharma Corp (CTIC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
CTI BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cell Therapeutics Acquires Pacritinib From S*BIO 11
Venture Financing 13
CTI BioPharma Announces Venture Debt Financing 13
Licensing Agreements 14
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
Equity Offering 17
CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17
CTI BioPharma Raises USD69 Million in Public Offering of Shares 18
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22
CTI BioPharma Raises USD50 Million in Public Offering of Shares 24
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28
Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30
Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34
CTI BioPharma Corp-Key Competitors 36
CTI BioPharma Corp-Key Employees 37
CTI BioPharma Corp-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2018: CTI BioPharma reports third quarter 2018 financial results 39
Aug 02, 2018: CTI BioPharma reports second quarter 2018 financial results 40
May 03, 2018: CTI BioPharma Reports First Quarter 2018 Financial Results 42
Mar 07, 2018: CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45
Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 46
May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 47
Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 48
Corporate Communications 50
Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 50
Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 51
Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 52
Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 53
Product News 54
01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 54
Product Approvals 56
Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 56
Clinical Trials 57
Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 57
Other Significant Developments 59
Jan 25, 2018: CTI BioPharma Provides Corporate and European Regulatory Update 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List of Figure
List of Figures
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Therapeutics Acquires Pacritinib From S*BIO 11
CTI BioPharma Announces Venture Debt Financing 13
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17
CTI BioPharma Raises USD69 Million in Public Offering of Shares 18
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22
CTI BioPharma Raises USD50 Million in Public Offering of Shares 24
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28
Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30
Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34
CTI BioPharma Corp, Key Competitors 36
CTI BioPharma Corp, Key Employees 37
CTI BioPharma Corp, Subsidiaries 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.